John Xu
Director Ejecutivo en Jemincare Therapeutics Corp. .
Perfil
John Xu is the founder and Chief Executive Officer of Jemincare Therapeutics Corp.
which is founded in 2018.
He was also a Senior Vice President of Strategic Alliances at Abpro Corp.
from 2017 to 2019.
Dr. Xu holds a doctorate from Zhongshan Hospital Fudan University, a graduate degree from Chicago Medical School, and an MBA from the University of Colorado Colorado Springs.
Cargos activos de John Xu
| Empresas | Cargo | Inicio |
|---|---|---|
Jemincare Therapeutics Corp.
 Jemincare Therapeutics Corp. BiotechnologyHealth Technology Jemincare Therapeutics Corp. is a pharmaceutical company. It plans to in license the global and China rights of the large and small molecule clinical stage programs in therapeutic areas such as oncology, cardiovascular and kidney disease. The company was founded by John Xu in November 2018 and is headquartered in Princeton, NJ. | Director Ejecutivo | 01/11/2018 |
Antiguos cargos conocidos de John Xu.
| Empresas | Cargo | Fin |
|---|---|---|
| ABPRO CORPORATION | Corporate Officer/Principal | - |
Formación de John Xu.
| Zhongshan Hospital Fudan University | Doctorate Degree |
| University of Colorado Colorado Springs | Masters Business Admin |
| Chicago Medical School | Graduate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Abpro Corp.
 Abpro Corp. BiotechnologyHealth Technology Abpro Corp. operates as a biotechnology company which develops antibody therapeutics for severe and life threatening diseases. It focusses on novel antibody constructs for immuno-oncology, ophthalmology, and autoimmunity. The company was founded by Ian Chan and Eugene Y. Chan in 2007 and is headquartered in Woburn, MA. | Health Technology |
Jemincare Therapeutics Corp.
Jemincare Therapeutics Corp. BiotechnologyHealth Technology Jemincare Therapeutics Corp. is a pharmaceutical company. It plans to in license the global and China rights of the large and small molecule clinical stage programs in therapeutic areas such as oncology, cardiovascular and kidney disease. The company was founded by John Xu in November 2018 and is headquartered in Princeton, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- John Xu